The Mitochondrial Free Radical Theory of Aging - Supernova: Pliki

The Mitochondrial Free Radical Theory of Aging - Supernova: Pliki The Mitochondrial Free Radical Theory of Aging - Supernova: Pliki

pliki.supernova.com.pl
from pliki.supernova.com.pl More from this publisher
15.01.2013 Views

78 The Mitochondrial Free Radical Theory of Aging line tended to behave the same way, indicating strongly that the nuclear genotype had a strong influence on the relative selective advantage of the two genomes. I personally feel, in the light of this and other studies, that the ability of this technique to tell us about what happens in vivo in aging is less than many people claim; however, a very recent variation on the technique shows promise of changing that pessimism completely. The main challenge to the relevance to MiFRA of cybrid mtDNA segregation is that cybrids are rapidly dividing, and we have long known that rapidly-dividing cells tend to accumulate far less mutant mtDNA than non-dividing cells. Thus, any major selective advantage of mutant mtDNA in cybrids is necessarily due either to some curiosity of the particular mutation—which is in fact quite likely for those mutations that cause inherited diseases (see Section 6.6.5)—or to some non-physiological aspect of the cultured cells’ environment. The recent advance 73 is the use of cybrid technology on long-lived, non-dividing cells—muscle fibers. It has long been known that muscle precursor cells—myoblasts—can form into muscle fibers in culture but atrophy shortly afterwards. It is also long established that this atrophy can be prevented, and the fibers kept alive for several months, by coculturing them with neurons, particularly from the spinal cord. 74 What has now been achieved is the combination of this technique with the cybrid technique. Muscle precursor cells are first divested of their endogenous mtDNA, then repopulated with the mtDNA mixture of interest, and finally induced to fuse and form muscle fibers, which are kept alive by the neurons. It is thus now possible to study mitochondrial segregation in a population of genetically well-defined postmitotic cells. I have high hopes that this will lead to rapid progress, not least in the testing of the details of MiFRA that I will describe in later chapters. 6.6.4. Do mtDNA Point Mutations Accumulate? Naturally, the discovery of clonal amplification led to a search for a plausible mechanism whereby mtDNA mutations might derive their selective advantage. It was widely—and reasonably—felt that this might be easier if there were more information about which mutations accumulate during aging and which (if any) do not. Efforts to acquire such information were hampered, however, by the absence of a reliably accurate technology for measuring the concentration of a particular DNA sequence relative to another: standard PCR technology can only identify molecules of a different length than normal, so it cannot pick up point mutations. Also, even among deletions it was very clear that a great many mutations were possible, and the available techniques (which until recently did not include long PCR) could only assess the level of a few mutations per experiment. It was established quite quickly that particular mutations tended to be present at very low concentrations—0.1% or lower—even in postmitotic tissues of very aged individuals; but it was not possible to extend this to an estimate of the total mutation “load” in such tissues, because one never knew how many other, untested mutations were present at similar, or higher, levels or not at all. 75 It eventually became possible to gauge the overall levels of mtDNA deletions, due to the development of long PCR; but that still left open the question of the overall levels of point mutations. In due course, however, various refinements of PCR were developed which could identify point mutations, and several were demonstrated to accumulate with age in the same tissues. 76,77 But then, just as a consensus seemed to be forming on this point, it became controversial again as a result of experiments in the laboratory of Eric Schon, which established very convincingly that, in one particular section of the mtDNA, point mutations seemed never to occur at all—or, if they did, then they were not preferentially amplified in what others were coming to think of as the usual way. 78 Schon’s experiments used a PCR variant which was only applicable to a few places in the mitochondrial genome, but which, in those regions, was likely to give exceptionally accurate measurements of the real

History of the Mitochondrial Free Radical Theory of Aging, 1954-1995 concentrations of mutations. He therefore concluded that, most probably, point mutations never accumulate at all, and the contrary findings that had been published by other labs were artifacts of their experimental techniques. The other possibility, of course, was that there was something unusual about the particular region of the mtDNA that Schon had assayed (within the gene for ATPase subunit 6); but nothing of that kind was apparent, so this formal possibility was not—at that time—considered. 6.6.5. Inherited mtDNA-Linked Diseases; The Threshold Effect Just as it is difficult to extrapolate confidently from observations in rapidly dividing cells in vitro to the situation in non-dividing cells in vivo, so there are pitfalls in extrapolating from the phenotypes caused by genetic abnormalities to those that exist in normal aging. It is very tempting—and by no means always fruitless—to do this when the macroscopic phenotype of the disorder resembles accelerated aging, such as in Werner’s syndrome. It is equally tempting when the similarity is at a microscopic scale, and, indeed, several disorders exist in which mutant mtDNA appears to accumulate in a way similar to that in normal aging, but faster, often leading to early mortality. The similarities are great: the same tissues (non-dividing ones, particularly those with high energy demand) are most affected, and the levels of activity of mt-coded enzymes (such as cytochrome c oxidase) exhibit the same mosaic, “all-or-none” distribution with some cells (or fiber segments) having no activity while the rest have normal activity 79 The differences are also rather striking, however, and immediately give reason for caution. One great potential value of these diseases for the study of mtDNA dysfunction is that they are caused by the presence of the same mutation in every affected cell, so that the total level of mutant mtDNA in a tissue sample can be assessed quite accurately, in contrast to the situation in normal aging discussed in the previous section. But when this is done, patients are often found to have very large amounts of mutant mtDNA—sometimes over 50% by the time their symptoms have become severe. 80,81 The shortcomings of quantitative PCR (especially of point mutations) are considerable, but histochemical assays of enzymatic activity (which of course detect point mutations just as well as deletions) had by the early 1990s clearly excluded the possibility that the total mtDNA mutation load reached such levels in normal aging. This could be (and indeed has been: see Chapter 9) seen as a challenge to the relevance of mtDNA decline in aging, since the survival—albeit in poor health—of people with lots of mtDNA damage surely meant that the low levels seen in normal aging were essentially harmless. But the alternative interpretation is that these inherited mutations are not knockouts, but in fact only reduce the OXPHOS activity of cells by a rather small degree. Most spontaneous mutations, by contrast, would be severe,* and would therefore have a phenotypic effect when present at much lower levels. This interpretation makes sense of the curious observation that all known inherited, disease-causing mtDNA mutations in protein-coding genes are missense mutations, which change one amino acid, as opposed to deletions or nonsense mutations, which remove or truncate the encoded protein and are therefore generally more severe. (This is in contrast to sporadic, non-inherited mtDNA-linked diseases, which exhibit similar symptoms and are often associated with mtDNA deletions.) 82 These mutations (and those in tRNA genes) are known to inhibit OXPHOS severely in vitro, 81 but again one must be cautious, because this * If most spontaneous mutations are deletions then this is certainly true, but if most are point mutations then it needs some defending, since typical amino acid substitutions in typical genes do not completely abolish their function. But it must be taken into account that all the mt-coded proteins are subunits of complex multimeric enzymes; proteins of this sort are more sensitive to amino acid changes than average. 79

78<br />

<strong>The</strong> <strong>Mitochondrial</strong> <strong>Free</strong> <strong>Radical</strong> <strong>The</strong>ory <strong>of</strong> <strong>Aging</strong><br />

line tended to behave the same way, indicating strongly that the nuclear genotype had a<br />

strong influence on the relative selective advantage <strong>of</strong> the two genomes.<br />

I personally feel, in the light <strong>of</strong> this and other studies, that the ability <strong>of</strong> this technique<br />

to tell us about what happens in vivo in aging is less than many people claim; however, a<br />

very recent variation on the technique shows promise <strong>of</strong> changing that pessimism completely.<br />

<strong>The</strong> main challenge to the relevance to MiFRA <strong>of</strong> cybrid mtDNA segregation is that cybrids<br />

are rapidly dividing, and we have long known that rapidly-dividing cells tend to accumulate<br />

far less mutant mtDNA than non-dividing cells. Thus, any major selective advantage <strong>of</strong><br />

mutant mtDNA in cybrids is necessarily due either to some curiosity <strong>of</strong> the particular<br />

mutation—which is in fact quite likely for those mutations that cause inherited diseases<br />

(see Section 6.6.5)—or to some non-physiological aspect <strong>of</strong> the cultured cells’ environment.<br />

<strong>The</strong> recent advance 73 is the use <strong>of</strong> cybrid technology on long-lived, non-dividing<br />

cells—muscle fibers. It has long been known that muscle precursor cells—myoblasts—can<br />

form into muscle fibers in culture but atrophy shortly afterwards. It is also long established<br />

that this atrophy can be prevented, and the fibers kept alive for several months, by coculturing<br />

them with neurons, particularly from the spinal cord. 74 What has now been achieved is the<br />

combination <strong>of</strong> this technique with the cybrid technique. Muscle precursor cells are first<br />

divested <strong>of</strong> their endogenous mtDNA, then repopulated with the mtDNA mixture <strong>of</strong> interest,<br />

and finally induced to fuse and form muscle fibers, which are kept alive by the neurons.<br />

It is thus now possible to study mitochondrial segregation in a population <strong>of</strong> genetically<br />

well-defined postmitotic cells. I have high hopes that this will lead to rapid progress, not<br />

least in the testing <strong>of</strong> the details <strong>of</strong> MiFRA that I will describe in later chapters.<br />

6.6.4. Do mtDNA Point Mutations Accumulate?<br />

Naturally, the discovery <strong>of</strong> clonal amplification led to a search for a plausible mechanism<br />

whereby mtDNA mutations might derive their selective advantage. It was widely—and<br />

reasonably—felt that this might be easier if there were more information about which<br />

mutations accumulate during aging and which (if any) do not. Efforts to acquire such<br />

information were hampered, however, by the absence <strong>of</strong> a reliably accurate technology for<br />

measuring the concentration <strong>of</strong> a particular DNA sequence relative to another: standard<br />

PCR technology can only identify molecules <strong>of</strong> a different length than normal, so it cannot<br />

pick up point mutations. Also, even among deletions it was very clear that a great many<br />

mutations were possible, and the available techniques (which until recently did not include<br />

long PCR) could only assess the level <strong>of</strong> a few mutations per experiment. It was established<br />

quite quickly that particular mutations tended to be present at very low concentrations—0.1%<br />

or lower—even in postmitotic tissues <strong>of</strong> very aged individuals; but it was not possible to<br />

extend this to an estimate <strong>of</strong> the total mutation “load” in such tissues, because one never<br />

knew how many other, untested mutations were present at similar, or higher, levels or not at<br />

all. 75 It eventually became possible to gauge the overall levels <strong>of</strong> mtDNA deletions, due to<br />

the development <strong>of</strong> long PCR; but that still left open the question <strong>of</strong> the overall levels <strong>of</strong><br />

point mutations.<br />

In due course, however, various refinements <strong>of</strong> PCR were developed which could identify<br />

point mutations, and several were demonstrated to accumulate with age in the same<br />

tissues. 76,77 But then, just as a consensus seemed to be forming on this point, it became<br />

controversial again as a result <strong>of</strong> experiments in the laboratory <strong>of</strong> Eric Schon, which<br />

established very convincingly that, in one particular section <strong>of</strong> the mtDNA, point mutations<br />

seemed never to occur at all—or, if they did, then they were not preferentially amplified in<br />

what others were coming to think <strong>of</strong> as the usual way. 78 Schon’s experiments used a PCR<br />

variant which was only applicable to a few places in the mitochondrial genome, but which,<br />

in those regions, was likely to give exceptionally accurate measurements <strong>of</strong> the real

Hooray! Your file is uploaded and ready to be published.

Saved successfully!

Ooh no, something went wrong!